AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1981, the company has established itself as a leader in developing innovative therapies primarily focused on women's health, maternal health, and supportive care. With a strong presence in North America and expanding operations in international markets, AMAG is dedicated to addressing unmet medical needs. The company’s core products, including treatments for iron deficiency anaemia and preterm labour, are distinguished by their commitment to safety and efficacy. AMAG's notable achievements include a robust pipeline of therapies that leverage cutting-edge research and development. As a trusted name in the biopharmaceutical sector, AMAG Pharmaceuticals continues to enhance patient outcomes and solidify its market position through strategic partnerships and a focus on innovation.
DitchCarbon Score
How does AMAG Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AMAG Pharmaceuticals, Inc.'s score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AMAG Pharmaceuticals, Inc.'s reported carbon emissions
In 2022, AMAG Pharmaceuticals, Inc. reported total carbon emissions of approximately 165 kg CO2e, encompassing Scope 1 and 2 emissions. This figure reflects a slight decrease from 2021, when emissions were about 168 kg CO2e. The company has not disclosed any Scope 3 emissions data for the years reported. AMAG Pharmaceuticals has not set specific reduction targets or initiatives, nor does it participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The absence of formal commitments indicates a potential area for growth in their climate strategy. The emissions data is not cascaded from any parent organisation, and all figures are directly reported by AMAG Pharmaceuticals, Inc. As the company continues to navigate its environmental impact, further transparency and commitment to reduction strategies may enhance its sustainability profile in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 104,400,000 | 000,000,000 | 000,000,000 | - | - |
| Scope 2 | - | - | - | - | - |
| Scope 3 | - | - | 0,000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AMAG Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
